Price movement over the last 24 hours
American Financial Group Inc vs Bristol-Myers Squibb Co — how do they compare? American Financial Group Inc trades at $141.63 (market cap $11.86B), while Bristol-Myers Squibb Co trades at $57.69 (market cap $118.38B). The key difference: Bristol-Myers Squibb Co is far larger — about 10× American Financial Group Inc's market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.35%). Which is the better fit depends on your goals.
| AFG | BMY | |
|---|---|---|
Market Cap | $11.86B | $118.38B |
Sector | Financials | Health |
52-Week High | $148.71 | $62.37 |
52-Week Low | $122.42 | $42.60 |
Enterprise Value | $12.33B | $154.32B |
Dividend Yield | 2.46% | 4.35% |
Signals from Pluang's Aura AI — not financial advice
AFG trades at $142.80, up 0.04% with a bullish technical outlook. The stock shows strong profitability with 10.84% net margin and 19.38% ROE, though Q1 2026 earnings missed estimates. Recent dividend declarations of $0.88 per share highlight shareholder returns. Analyst consensus is mixed with 41% buy ratings and a $149 price target, representing 4.3% upside from current levels.
AFG offers moderate upside potential with solid fundamentals and consistent dividends, but faces execution risks after recent earnings miss. The insurance sector exposure provides stability, though competitive pressures and regulatory changes remain key watchpoints for investors seeking steady returns with income generation.
Bristol Myers Squibb (BMY) trades at $57.97, down 0.28% today, with a bullish technical signal and consistent earnings beats. The company maintains strong profitability with a 15.01% net income margin and a 4.3% dividend yield. Recent news highlights its growth portfolio now comprising over 54% of revenues, though patent cliff concerns persist. Cash flow from operations remains robust at $14.16B for 2025, supporting dividend sustainability.
BMY offers value with a P/E of 15.88 below industry averages, but faces significant patent expiration risks that could pressure future revenues. Analyst consensus is mixed with a $64.33 price target suggesting 11% upside. The stock is a cash flow machine with upside potential if new drug pipelines deliver, though investors must weigh growth execution against legacy portfolio declines.
Trailing returns across standard periods
Latest headlines on both assets
American Financial Group Inc is a holding company that is engaged primarily in property and casualty insurance services. The company has a focus on specialized commercial products for businesses. American also has annuity operations that are focused on sales of traditional fixed and fixed-indexed annuities in the education, bank, and individual markets. American's insurance operations are conducted through the Great American Insurance Group. The group writes business in all 50 of the United States, primarily through independent agents and brokers.
Read more on AFG →Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →